Indian unit of Pfizer reports 3 percent rise in Q4 profit
Separately, parent Pfizer Inc reported higher-than-expected first-quarter revenue and profit, helped by demand for its COVID-19 products.
Bengaluru: Pfizer Ltd, the Indian unit of US pharmaceutical group Pfizer Inc, on Monday reported a 3.1 per cent rise in fourth-quarter profit, helped by lower raw material expenses.
Net profit for the quarter ended March 31 rose to 1.30 billion rupees ($15.90 million) from 1.26 billion rupees a year ago, while revenue rose 4.2 per cent.
Pfizer also declared a final dividend of 35 rupees per share and a special dividend of 5 rupees per share.
WHY IT MATTERS
Pfizer's pharmaceutical segment has a portfolio of over 150 products. Separately, parent Pfizer Inc reported higher-than-expected first-quarter revenue and profit, helped by demand for its COVID-19 products.
In India, rival Cipla Ltd posted a 45.2 per cent increase in fourth-quarter profit, while Novartis India Ltd reported a quarterly profit compared with a loss a year ago.
Abbott India Ltd and GlaxoSmithKline Pharmaceuticals Ltd are scheduled to report its quarterly results later this week.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd